Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania Show more

Location: 125 Strafford Avenue, Wayne, PA, 19087, United States | Website: https://palvellatx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

306.2M

52 Wk Range

$7.21 - $29.27

Previous Close

$27.70

Open

$27.80

Volume

30,635

Day Range

$26.98 - $28.00

Enterprise Value

186.7M

Cash

75.63M

Avg Qtr Burn

-4.127M

Insider Ownership

22.87%

Institutional Own.

47.68%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.